TIDMFARN
RNS Number : 1926S
Faron Pharmaceuticals Oy
21 June 2018
Faron Pharmaceuticals Oy
("Faron" or the "Company")
PDMR Dealings and
Person Closely Associated with PDMR Dealings
TURKU - FINLAND, 21 June 2018 - Faron Pharmaceuticals Ltd
("Faron") (LON: FARN), the clinical stage biopharmaceutical
company, announces that on 21 June 2018 it was notified of the
following PDMR and persons closely associated dealings.
On 19 June 2018, Mr Matti Manner, the Non-Executive Director of
Faron had acquired 15,500 ordinary shares in Faron at a price of 56
pence per ordinary share, and a person closely associated with him
had acquired 7,900 ordinary shares in Faron at a price of 56 pence
per ordinary share.
On 20 June 2018, Mr Yrjö Wichmann, Chief Financial Officer of
Faron had acquired 5,200 ordinary shares in Faron at a price of 67
pence per ordinary share and on 21 June 2018, Dr. Pessi Honkasalo,
Corporate Legal Counsel of Faron had acquired 1,500 ordinary shares
in Faron at a price of 75 pence per ordinary share.
On 21 June 2018, Dr Matti Karvonen, Medical Director of Faron,
had acquired 15,000 ordinary shares in Faron at a price of 56 pence
per ordinary share and a person closely associated with him had
acquired 31,000 ordinary shares in Faron at a price of 57 pence per
ordinary share.
On 21 June 2018, Dr. Markku Jalkanen, Chief Executive Officer of
Faron, had acquired 12,000 ordinary shares and a person closely
associated with him had acquired 24,000 ordinary shares in Faron at
a price of 71 pence per ordinary share. Also on 21 June 2018, Dr.
Juho Jalkanen, Chief Development Officer of Faron had acquired
12,000 ordinary shares in Faron at a price of 71 pence per ordinary
share.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
---- -----------------------------------------------------------------------------------------
a. Name Matti Manner
Susanna Hedenström
Yrjö Wichmann
Pessi Honkasalo
Matti Karvonen
Minja Pfeiffer
Markku Jalkanen
Mehto Saima Kuolinpesä
Juho Jalkanen
------------------------------------------------------------
2 Reason for notification
--------------------------- ------------------------------------------------------------
a. Position/Status Person discharging managerial responsibilities
/ person closely associated
- Non-Executive Director and a person closely
associated with him
- Chief Financial Officer
- Corporate Legal Counsel
- Medical Director and a person closely
associated with him
- Chief Executive Officer and a person closely
associated with him
- Chief Development Officer
--------------------------- ------------------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
--------------------------- ------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
---------------------------
b. LEI 7437009H31TO1DC0EB42
--------------------------- ------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- -----------------------------------------------------------------------------------------
a. Description of Ordinary shares
the financial
instrument, type ISIN: FI4000153309
of instrument
Identification
Code
--------------------------- ------------------------------------------------------------
b. Nature of the Purchase of ordinary shares
transaction
--------------------------- ------------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
--------------------------- ---------------
56.00 GBPp 15,500
56.00 GBPp 7,900
67.00 GBPp 5,200
75.00 GBPp 1,500
56.00 GBPp 15,000
57.00 GBPp 31,000
71.00 GBPp 12,000
71.00 GBPp 24,000
71.00 GBPp 12,000
----------------------------------------------------- ------------
d. Aggregated information
- Aggregated Volume N/A
- Price N/A
--------------------------- ------------------------------------------------------------
e. Date of the transaction June 19, 2018, June 20, 2018 and June 21,
2018
--------------------------- ------------------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM Market
--------------------------- ------------------------------------------------------------
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey
Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com
Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500
About Faron Pharmaceuticals Ltd
Faron (AIM:FARN) is a clinical stage biopharmaceutical company
developing novel treatments for medical conditions with significant
unmet needs. The Company currently has a pipeline focusing on acute
organ traumas, vascular damage and cancer immunotherapy. The
Company's lead candidate Traumakine, to prevent vascular leakage
and organ failures, has completed a Phase III clinical trial in
Acute Respiratory Distress Syndrome ("ARDS"). An additional
European Phase II Traumakine trial is underway for the Rupture of
Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate
Clevegen is a ground breaking preclinical anti-Clever-1 antibody.
Clevegen has the ability to switch immune suppression to immune
activation in various conditions, with potential across oncology,
infectious disease and vaccine development. This novel
macrophage-directed immuno-oncology switch called Tumour Immunity
Enabling Technology ("TIET") may be used alone or in combination
with other immune checkpoint molecules for the treatment of cancer
patients. Faron is based in Turku, Finland. Further information is
available at www.faron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFKDDPQBKDAAB
(END) Dow Jones Newswires
June 21, 2018 10:58 ET (14:58 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024